Ascendis Pharma A/S (NASDAQ:ASND) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Ascendis Pharma A/S (NASDAQ:ASND) have earned an average rating of “Moderate Buy” from the thirteen brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold rating and twelve have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $191.77.

ASND has been the topic of a number of research analyst reports. TD Cowen reduced their target price on Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating on the stock in a report on Friday, November 15th. Citigroup increased their price target on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Stifel Nicolaus boosted their price objective on shares of Ascendis Pharma A/S from $200.00 to $207.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Wedbush restated an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a report on Friday, November 15th. Finally, StockNews.com upgraded shares of Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th.

Ascendis Pharma A/S Stock Down 1.0 %

Shares of ASND stock opened at $136.38 on Friday. The firm has a market capitalization of $8.27 billion, a price-to-earnings ratio of -16.88 and a beta of 0.67. The stock has a fifty day moving average of $129.69 and a 200 day moving average of $132.81. Ascendis Pharma A/S has a 52 week low of $111.09 and a 52 week high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Several institutional investors have recently added to or reduced their stakes in ASND. Westfield Capital Management Co. LP lifted its holdings in shares of Ascendis Pharma A/S by 3.4% during the third quarter. Westfield Capital Management Co. LP now owns 5,133,766 shares of the biotechnology company’s stock valued at $766,523,000 after purchasing an additional 170,942 shares in the last quarter. Avoro Capital Advisors LLC lifted its position in Ascendis Pharma A/S by 5.8% during the second quarter. Avoro Capital Advisors LLC now owns 4,196,661 shares of the biotechnology company’s stock valued at $572,341,000 after purchasing an additional 229,995 shares during the period. Janus Henderson Group PLC lifted its holdings in shares of Ascendis Pharma A/S by 6.8% during the 3rd quarter. Janus Henderson Group PLC now owns 4,186,694 shares of the biotechnology company’s stock valued at $625,075,000 after buying an additional 267,881 shares during the period. Massachusetts Financial Services Co. MA lifted its holdings in Ascendis Pharma A/S by 9.1% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,866,986 shares of the biotechnology company’s stock valued at $278,760,000 after acquiring an additional 155,971 shares during the period. Finally, Groupama Asset Managment purchased a new position in Ascendis Pharma A/S in the third quarter worth about $60,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.